Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|June 16, 2022

People and Business News — 6/22

People News

WCG has appointed Sam Srivastava as Chief Executive Officer; Robert VanHees as Chief Financial and Administrative Officer; and Paul Mancinelli, PhD, as Chief Technology Officer.

mdgroup has charged its new VP, Product Delivery, Mohamad (Mo) Merhi with doubling the development team, and appointed LaQuinta Jernigan to Chief Operating Officer.

Dotmatics announced the additions of Larry Samuelson as Chief Legal Officer and Neil Frye as Chief People Officer.

AeroSafe Global announced Jessica Cao joined the company as Senior Vice President of Marketing.

Allucent, announced the appointment of Katy Moore as President of Clinical Pharmacology, Modeling and Simulation.

Walgreens announced several new hires including Kendal Whitlock as Head of Digital Optimization, RWE Clinical Trials; John Campbell as Head of Decentralized Clinical Trials; Liam Wood as Head of Product, RWE Clinical Trials, and Adam Samson as Head of Clinical Delivery Operations, RWE Clinical Trials.

Recognition

Vitalograph is celebrating 21 years as a clinical trials service provider.

mdgroup has been shortlisted as one of the UK's fastest-growing private companies in the inaugural Sunday Times 100 ranking.

For the seventh consecutive year, Celerion has been named recipient of the Life Science Leader and Clinical Leader’s CRO Leadership Awards in all five award categories.


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.